These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9801489)

  • 21. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonhematologic complications of erythropoietin therapy.
    Zhu X; Perazella MA
    Semin Dial; 2006; 19(4):279-84. PubMed ID: 16893404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Resistance to rHuEPO].
    Sułowicz W
    Przegl Lek; 1995; 52(3):88-9. PubMed ID: 7644681
    [No Abstract]   [Full Text] [Related]  

  • 24. Adjunctive therapy in anaemia management.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 5():56-9. PubMed ID: 12091609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron management in ESRD and the role of the nephrology nurse.
    Robbins KC; Senger JM; Kerhulas S; Fishbane S
    ANNA J; 1997 Apr; 24(2):265-72; quiz 273-4. PubMed ID: 9180431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients.
    Yamazaki C; Watanabe Y; Sakamoto N
    Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1233-42. PubMed ID: 8139135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human erythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.
    Besarab A
    Am J Nephrol; 1990; 10 Suppl 2():2-6. PubMed ID: 2260613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal disease. II. The clinical impact of recombinant human erythropoietin.
    Muirhead N
    J R Coll Physicians Lond; 1997; 31(2):125-30. PubMed ID: 9131506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of renal anemia in 2013].
    Gianella P; Martin PY; Stucker F
    Rev Med Suisse; 2013 Feb; 9(375):462-4, 466-7. PubMed ID: 23539813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin treatment in children with renal failure.
    Van Damme-Lombaerts R; Herman J
    Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfusion therapy: associated risks and alternative approaches.
    Picard VT; Sayers MH; Spinowitz BS; Richner RE
    ANNA J; 1990 Dec; 17(6):457-64. PubMed ID: 2256728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Personal experience with the use of human recombinant erythropoietin in the treatment of anemia in children with chronic renal insufficiency].
    Podracká L; Sasinka M; Roland R; Böör A
    Cesk Pediatr; 1992 May; 47(5):268-71. PubMed ID: 1638649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of anemia in erythropoietin-resistant hemodialysis patients.
    Dar Santos AE; Shalansky KF; Jastrzebski JP
    Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and anemia.
    Tong EM; Nissenson AR
    Semin Nephrol; 2001 Mar; 21(2):190-203. PubMed ID: 11245780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CQI in anemia management: using the fishbone approach to improve outcomes. Case study of the anemic patient.
    Breiterman-White R
    ANNA J; 1999 Apr; 26(2):254-7. PubMed ID: 10418356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.